Abstract
H(2)S is an endogenous gas signaling molecule and its multiple biological effects have been demonstrated. The abnormal level of H(2)S is closely related to the occurrence and development of many diseases, and H(2)S donors has important pharmacological implications. In recent years, H(2)S donors represented by ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) are often used to synthesize new 'conjugate' compounds that can release H(2)S and parent drugs. These hybrids retain the pharmacological activity of the parent drugs and H(2)S and have a synergistic effect. ADTOH and parent drug hybrids have become one of the important strategies for the development of H(2)S donor conjugate drugs. This review summarizes molecular hybrids between ADTOH and clinical drugs to provide new ideas for the study of H(2)S donor drug design.